22 results on '"Ando, Naokatsu"'
Search Results
2. Analysis of cross-reactivity among flaviviruses using sera of patients with dengue showed the importance of neutralization tests with paired serum samples for the correct interpretations of serological test results for dengue
- Author
-
Maeki, Takahiro, Tajima, Shigeru, Ando, Naokatsu, Wakimoto, Yuji, Hayakawa, Kayoko, Kutsuna, Satoshi, Kato, Fumihiro, Taniguchi, Satoshi, Nakayama, Eri, Lim, Chang-Kweng, and Saijo, Masayuki
- Published
- 2023
- Full Text
- View/download PDF
3. A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo
- Author
-
Mizushima, Daisuke, Takano, Misao, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Aoki, Takahiro, Watanabe, Koji, Ishizuka, Naoki, and Oka, Shinichi
- Published
- 2022
- Full Text
- View/download PDF
4. Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus
- Author
-
Ando, Naokatsu, Nishijima, Takeshi, Mizushima, Daisuke, Inaba, Yosuke, Kawasaki, Yohei, Kikuchi, Yoshimi, Oka, Shinichi, and Gatanaga, Hiroyuki
- Published
- 2021
- Full Text
- View/download PDF
5. Electrocautery ablation therapy for anal intraepithelial carcinoma: A study protocol
- Author
-
Ando, Naokatsu, Mizushima, Daisuke, Takano, Misao, Kitamura, Hiroshi, Shiojiri, Daisuke, Nakamoto, Takato, Aoki, Takahiro, Watanabe, Koji, Uemura, Haruka, Gatanaga, Hiroyuki, and Oka, Shinichi
- Published
- 2022
- Full Text
- View/download PDF
6. Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan
- Author
-
Shiojiri, Daisuke, Mizushima, Daisuke, Takano, Misao, Watanabe, Koji, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Aoki, Takahiro, Tanuma, Junko, Tsukada, Kunihisa, Teruya, Katsuji, Kikuchi, Yoshimi, Gatanaga, Hiroyuki, and Oka, Shinichi
- Published
- 2021
- Full Text
- View/download PDF
7. Identification of viral protein R of human immunodeficiency virus-1 (HIV) and interleukin-6 as risk factors for malignancies in HIV-infected individuals: A cohort study.
- Author
-
Matsunaga, Akihiro, Ando, Naokatsu, Yamagata, Yuko, Shimura, Mari, Gatanaga, Hiroyuki, Oka, Shinichi, and Ishizaka, Yukihito
- Subjects
- *
PROTEOMICS , *INTERLEUKIN-6 , *HIV , *PROPENSITY score matching , *ENZYME-linked immunosorbent assay - Abstract
Background: Despite effective antiretroviral therapy, patients with human immunodeficiency virus type-1 (HIV) suffer from a high frequency of malignancies, but related risk factors remain elusive. Here, we focused on blood-circulating viral protein R (Vpr) of HIV, which induces proinflammatory cytokine production and genotoxicity by exogenous functions. Methods and findings: A total 404 blood samples of HIV patients comprising of 126 patients with malignancies (tumor group) and 278 patients without malignancies (non-tumor group), each of 96 samples was first selected by one-to-one propensity score matching. By a detergent-free enzyme-linked immunosorbent assays (detection limit, 3.9 ng/mL), we detected Vpr at a higher frequency in the matched tumor group (56.3%) than in the matched non-tumor group (39.6%) (P = 0.030), although there was no different distribution of Vpr levels (P = 0.372). We also detected anti-Vpr immunoglobulin (IgG), less frequently in the tumor group compared with the tumor group (22.9% for tumor group vs. 44.8% for non-tumor group, P = 0.002), and the proportion of patients positive for Vpr but negative of anti-Vpr IgG was significantly higher in the tumor group than in the non-tumor group (38.6% vs. 15.6%, respectively, P < 0.001). Additionally, Interleukin-6 (IL-6), the levels of which were high in HIV-1 infected patients (P < 0.001) compared to non-HIV-infected individuals, was significantly higher in advanced cases of tumors (P < 0.001), and IL-6 level was correlated with Vpr in the non-tumor group (P = 0.010). Finally, multivariate logistic regression analysis suggested a positive link of Vpr with tumor occurrence in HIV patients (P = 0.002). Conclusion: Vpr and IL-6 could be risk factors of HIV-1 associated malignancies, and it would be importance to monitor these molecules for well managing people living with HIV-1. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial.
- Author
-
Ando, Naokatsu, Mizushima, Daisuke, Omata, Kazumi, Nemoto, Takashi, Inamura, Natsumi, Hiramoto, Saori, Takano, Misao, Aoki, Takahiro, Watanabe, Koji, Uemura, Haruka, Shiojiri, Daisuke, Yanagawa, Yasuaki, Tanuma, Junko, Teruya, Katsuji, Kikuchi, Yoshimi, Gatanaga, Hiroyuki, and Oka, Shinichi
- Subjects
- *
HIV-positive persons , *COMBINATION drug therapy , *CLINICAL trials , *PROBENECID (Drug) , *SYPHILIS , *SERODIAGNOSIS , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *COMPARATIVE studies , *RESEARCH funding , *STATISTICAL sampling , *AMOXICILLIN , *PATIENT safety - Abstract
Background Amoxicillin plus probenecid is an alternative to intramuscular benzathine penicillin G for treating syphilis in the United Kingdom. Low-dose amoxicillin is an alternative treatment option used in Japan. Methods We conducted an open-label, randomized, controlled, non-inferiority trial between 31 August 2018, and 3 February 2022, to compare 1500 mg low-dose amoxicillin monotherapy with the combination of 3000 mg amoxicillin and probenecid (non-inferiority margin 10%). Patients with human immunodeficiency virus (HIV) infection and syphilis were eligible. The primary outcome was the cumulative serological cure rate within 12 months post-treatment, measured using the manual rapid plasma reagin card test. Secondary outcomes included safety assessment. Results A total of 112 participants were randomized into 2 groups. Serological cure rates within 12 months were 90.6% and 94.4% with the low-dose amoxicillin and combination regimens, respectively. Serological cure rates for early syphilis within 12 months were 93.5% and 97.9% with the low-dose amoxicillin and combination regimens, respectively. Non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid overall and for early syphilis was not confirmed. No significant side effects were detected. Conclusions This is the first randomized controlled trial to demonstrate a high efficacy of amoxicillin-based regimens for treating syphilis in patients with HIV infection, and the non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid was not seen. Therefore, amoxicillin monotherapy could be a good alternative to intramuscular benzathine penicillin G with fewer side effects. However, further studies comparing with benzathine penicillin G in different populations and with larger sample sizes are needed. Trials Registration (UMIN000033986). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study.
- Author
-
Ando, Naokatsu, Mizushima, Daisuke, Takano, Misao, Mitobe, Morika, Kobayashi, Kai, Kubota, Hiroaki, Miyake, Hirofumi, Suzuki, Jun, Sadamasu, Kenji, Aoki, Takahiro, Watanabe, Koji, Uemura, Haruka, Yanagawa, Yasuaki, Gatanaga, Hiroyuki, and Oka, Shinichi
- Subjects
- *
MYCOPLASMA , *COHORT analysis , *LONGITUDINAL method , *INFECTION , *WORLD health - Abstract
Background Mycoplasma genitalium has a tendency to develop macrolide and quinolone resistance. Objectives We investigated the microbiological cure rate of a 7 day course of sitafloxacin for the treatment of rectal and urogenital infections in MSM. Patients and methods This open-label, prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan from January 2019 to August 2022. Patients with M. genitalium urogenital or rectal infections were included. The patients were treated with sitafloxacin 200 mg daily for 7 days. M. genitalium isolates were tested for parC , gyrA and 23S rRNA resistance-associated mutations. Results In total, 180 patients (median age, 35 years) were included in this study, of whom 77.0% (97/126) harboured parC mutations, including 71.4% (90/126) with G248T(S83I) in parC , and 22.5% (27/120) harboured gyrA mutations. The median time to test of cure was 21 days. The overall microbiological cure rate was 87.8%. The cure rate was 100% for microbes harbouring parC and gyrA WTs, 92.9% for microbes harbouring parC G248T(S83I) and gyrA WT, and 41.7% for microbes harbouring parC G248T(S83I) and gyrA with mutations. The cure rate did not differ significantly between urogenital and rectal infection (P = 0.359). Conclusions Sitafloxacin monotherapy was highly effective against infection caused by M. genitalium , except strains with combined parC and gyrA mutations. Sitafloxacin monotherapy can be used as a first-line treatment for M. genitalium infections in settings with a high prevalence of parC mutations and a low prevalence of gyrA mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
- Author
-
Mizushima, Daisuke, Takano, Misao, Aoki, Takahiro, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Watanabe, Koji, Gatanaga, Hiroyuki, Kikuchi, Yoshimi, and Oka, Shinichi
- Published
- 2023
- Full Text
- View/download PDF
11. Effect of unintended short-term 3.0 g/day amoxicillin and probenecid treatment for early syphilis on patients with HIV-1 infection.
- Author
-
Inada, Makoto, Ando, Naokatsu, Mizushima, Daisuke, Kikuchi, Yoshimi, Gatanaga, Hiroyuki, and Oka, Shinichi
- Published
- 2023
- Full Text
- View/download PDF
12. Pseudo-renal failure: bladder rupture with urinary ascites
- Author
-
Matsumura, Masami, Ando, Naokatsu, Kumabe, Ayako, and Dhaliwal, Gurpreet
- Published
- 2015
- Full Text
- View/download PDF
13. Unmasking latent extrapulmonary tuberculosis with newly diagnosed HIV-1 infection in a COVID-19 patient with prolonged fever.
- Author
-
Hirata, Kaiho, Watanabe, Koji, Sasaki, Takeshi, Yoshimasu, Takashi, Shimomura, Akihiko, Ando, Naokatsu, Yanagawa, Yasuaki, Mizushima, Daisuke, Teruya, Katsuji, Kikuchi, Yoshimi, Oka, Shinichi, and Tsukada, Kunihisa
- Subjects
LATENT tuberculosis ,COVID-19 ,FEVER ,LATENT infection ,HIV ,LYMPHADENITIS ,EXTRAPULMONARY tuberculosis - Abstract
Prolonged fever is a common symptom of COVID-19 infection. However, other febrile diseases continue during the pandemic. Herein, we report a COVID-19-infected patient with prolonged fever despite the lack of oxygen requirement, who was finally diagnosed with tuberculotic lymphadenitis and HIV-1 infection. All symptoms improved rapidly after the initiation of antituberculosis medications. Tuberculosis is an important differential diagnosis for patients with prolonged fever during the COVID-19 pandemic. It is possible that COVID-19 infection could serve to unmask latent infections via a cytokine storm. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Efficacy of 1 g Ceftriaxone Monotherapy Compared to Dual Therapy With Azithromycin or Doxycycline for Treating Extragenital Gonorrhea Among Men Who Have Sex With Men.
- Author
-
Aoki, Takahiro, Mizushima, Daisuke, Takano, Misao, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Watanabe, Koji, Gatanaga, Hiroyuki, Kikuchi, Yoshimi, and Oka, Shinichi
- Subjects
EPIDEMIOLOGY of sexually transmitted diseases ,DRUG efficacy ,CEFTRIAXONE ,GONORRHEA ,SCIENTIFIC observation ,PHARYNGEAL diseases ,CONFIDENCE ,CONFIDENCE intervals ,CLINICAL trials ,TIME ,ORAL drug administration ,RECTAL diseases ,DOXYCYCLINE ,FISHER exact test ,COMPARATIVE studies ,MEN who have sex with men ,AZITHROMYCIN ,CHLAMYDIA trachomatis ,DATA analysis software ,LONGITUDINAL method - Abstract
Background Evidence on efficacy of high-dose ceftriaxone monotherapy for extragenital Neisseria gonorrhoeae (NG) infection is lacking. Methods A cohort of men who have sex with men (MSM) were tested for NG/ Chlamydia trachomatis (CT) every 3 months, in a single-center observational study in Tokyo, Japan. MSM aged > 19 years diagnosed with extragenital NG infection between 2017 and 2020 were included. A single dose of 1 g ceftriaxone monotherapy was provided, while dual therapy with a single oral dose of 1 g azithromycin or 100 mg doxycycline administered orally twice daily for 7 days were given, for those coinfected with CT, according to infected sites. Efficacy of these treatments was calculated by the number of NG-negative subjects at test-of-cure divided by the number of subjects treated. Fisher exact tests were used to compare the efficacy between the 2 groups. Results Of 320 cases diagnosed with extragenital NG, 208 were treated with monotherapy and 112 were treated with dual therapy. The efficacy against total, pharyngeal, and rectal infections was 98.1% (204/208, 95% confidence interval [CI]: 95.2–99.3%), 97.8% (135/138, 95% CI: 93.8–99.4%), and 98.6% (69/70, 95% CI: 92.3–99.9%), respectively, in the monotherapy group, whereas the corresponding efficacy in the dual therapy was 95.5% (107/112, 95% CI: 90.0–98.1%), 96.1% (49/51, 95% CI: 86.8–99.3%), and 95.1% (58/61, 95% CI: 86.5–98.7%), respectively. No significant difference in the corresponding efficacy was observed between the two groups (P = .29, P = .61, P = .34, respectively). Conclusions High-dose ceftriaxone monotherapy is as effective as dual therapy for extragenital NG among MSM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Modified self-obtained pooled sampling to screen for and infections in men who have sex with men.
- Author
-
Naokatsu Ando, Daisuke Mizushima, Koji Watanabe, Misao Takano, Daisuke Shiojiri, Haruka Uemura, Takahiro AOKI, Yasuaki Yanagawa, Yoshimi Kikuchi, Shinichi Oka, Hiroyuki Gatanaga, Ando, Naokatsu, Mizushima, Daisuke, Watanabe, Koji, Takano, Misao, Shiojiri, Daisuke, Uemura, Haruka, Aoki, Takahiro, Yanagawa, Yasuaki, and Kikuchi, Yoshimi
- Abstract
Objectives: To assess whether pooled sample testing with nucleic acid amplification tests was a potential alternative to three single-site sample testing to screen for Chlamydia trachomatis and Neisseria gonorrhoeae infections in asymptomatic men who have sex with men.Methods: We prospectively compared pooled sample testing with single-site sample testing in asymptomatic MSM. Self-obtained paired rectal samples, one gargle sample and one first-void urine sample were collected from participants to generate two sets of samples: one for pooled sample testing and the other for single-site testing. We used modified pooled sampling, which is defined as the use of gargle samples, instead of swabs, for the pooled sample to test for pharyngeal infection.Results: This study included 513 MSM. The positive rates of C. trachomatis and N. gonorrhoeae were 20.3% and 11.7%, respectively, for single-site sample testing. Compared with the sensitivity of single-site testing as the gold standard, the sensitivities of pooled sample testing for C. trachomatis and N. gonorrhoeae were 94.2% (95% CI 88.0% to 97.3%) and 98.3% (95% CI 90.9% to 99.9%), respectively. The concordance rate and kappa coefficient were 98.3% (95% CI 96.7% to 99.2%) and 0.945 (95% CI 0.859 to 1.000), respectively, for C. trachomatis and 98.8% (95% CI 90.1% to 100%) and 0.943 (95% CI 0.857 to 1.000), respectively, for N. gonorrhoeae.Conclusions: The modified pooled sampling had a comparably high consistency with single-site sample testing. The results strongly suggest that the gargle sample is suitable as a part of pooled sample for STI screening of C. trachomatis and N. gonorrhoeae. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Local radiotherapy for chemotherapy-refractory Kaposi's sarcoma in an HIV-infected patient: A case report and literature review.
- Author
-
Yoshitomi, Yutaro, Kawashima, Akira, Nakayama, Hidetsugu, Nakamoto, Takato, Ando, Naokatsu, Uemura, Haruka, Mizushima, Daisuke, Aoki, Takahiro, Tanuma, Junko, Teruya, Katsuji, Gatanaga, Hiroyuki, and Watanabe, Koji
- Subjects
- *
KAPOSI'S sarcoma , *LITERATURE reviews , *HIV , *ANTIRETROVIRAL agents , *RADIOTHERAPY - Abstract
Human immunodeficiency virus-associated Kaposi's sarcoma (HIV-KS) is a well-documented vascular tumor with a pathogenesis involving human herpesvirus-8 (HHV-8) infection. While antiretroviral therapy (ART) and chemotherapy are effective for treating most KS cases, some become refractory. In this report, we present a case of a 58-year-old man with refractory HIV-KS treated with ART and chemotherapy. Chemotherapy was eventually discontinued due to an adverse reaction, and the patient presented with painful plantar lesions that impaired ambulation. With the exclusion of visceral metastases, localized radiotherapy was administered, which resulted in significant cosmetic and functional improvements. The patient regained ambulation and lived independently, receiving additional radiotherapy as needed. This case underscores the potential use of radiotherapy for the treatment of ART-resistant KS, particularly when the patient is unresponsive to conventional chemotherapy. It also highlights the need for future research in this area. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.
- Author
-
Ando N, Mizushima D, Shimizu Y, Uemura Y, Takano M, Mitobe M, Kobayashi K, Kubota H, Miyake H, Suzuki J, Sadamasu K, Nakamoto T, Aoki T, Watanabe K, Oka S, and Gatanaga H
- Abstract
Background: Mycoplasma genitalium is an emerging sexually transmitted pathogen associated with increasing antibiotic resistance. The current treatment guidelines recommend moxifloxacin-sequential therapy for macrolide-resistant Mgenitalium or strains with unknown resistance profiles. However, it is unclear whether sitafloxacin, a 4th-generation fluoroquinolone antibiotic, is effective against resistant strains., Objective: This study aims to assess and compare the efficacy and safety of sitafloxacin- and moxifloxacin-based treatment regimens for managing Mgenitalium infections., Methods: We will conduct this randomized controlled trial at multiple centers in Japan. Eligible participants include adults aged 18 years or older with a confirmed Mgenitalium infection, as determined through the nucleic acid amplification test. Patients will be randomly assigned using a stratified approach based on the treatment facility and infection site. The interventions comprise oral sitafloxacin (200 mg) daily for 7 days (with optional pretreatment of oral doxycycline, 200 mg, daily for up to 7 days), with a control group receiving oral doxycycline (200 mg) daily for 7 days followed by moxifloxacin (400 mg) daily for another 7 days. The primary outcome is the treatment success rate with a superiority margin of 10%, as confirmed through the nucleic acid amplification test. Secondary outcomes encompass changes in the bacterial load at the urogenital or rectal sites and the emergence of posttreatment-resistant mutant strains., Results: Enrollment commenced in June 2023 and will conclude in December 2024, with findings anticipated by 2025. The expected success rates fall within the range of 80% for sitafloxacin and 42% for moxifloxacin against Mgenitalium carrying the G248T (S83I) mutation, based on previous studies. Accordingly, with a 5% significance level (2-sided) and 80% statistical power, we aim to recruit 50 participants per group, factoring in a 10% expected dropout rate., Conclusions: This study will provide valuable insights into the efficacy and safety of sitafloxacin- versus moxifloxacin-based sequential therapy in treating Mgenitalium infections. These findings have the potential to influence clinical guidelines, favoring more effective therapeutic choices. The multicenter approach enhances the robustness of this study. However, a limitation is the potential insufficiency of statistical power to detect posttreatment-resistant mutant strains in each group, rendering posttreatment-resistance mutations a notable concern. In the future, we may need to increase the sample size to enhance power., Trial Registration: Japan Registry of Clinical Trials (jRCTs031230111); https://jrct.niph.go.jp/en-latest-detail/jRCTs031230111., International Registered Report Identifier (irrid): DERR1-10.2196/52565., (©Naokatsu Ando, Daisuke Mizushima, Yosuke Shimizu, Yukari Uemura, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota, Hirofumi Miyake, Jun Suzuki, Kenji Sadamasu, Takato Nakamoto, Takahiro Aoki, Koji Watanabe, Shinichi Oka, Hiroyuki Gatanaga. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 14.11.2023.)
- Published
- 2023
- Full Text
- View/download PDF
18. Recent changes in the reporting of STIs in Japan during the COVID-19 pandemic.
- Author
-
Ghaznavi C, Tanoue Y, Kawashima T, Eguchi A, Yoneoka D, Sakamoto H, Ueda P, Ishikane M, Ando N, Miyazato Y, and Nomura S
- Subjects
- Humans, Pandemics, Japan epidemiology, Syphilis epidemiology, Gonorrhea epidemiology, Acquired Immunodeficiency Syndrome epidemiology, HIV Infections epidemiology, COVID-19 epidemiology, Sexually Transmitted Diseases epidemiology, Condylomata Acuminata epidemiology, Chlamydia, Chlamydia Infections epidemiology
- Abstract
Objectives: The COVID-19 pandemic has had variable effects on the rates of STIs reported across the globe. This study sought to assess how the number of STI reports changed during the pandemic in Japan., Methods: We used national infectious disease surveillance data from the National Institute of Infectious Diseases (Tokyo, Japan) for the period between January 2013 and December 2021. We compared reported rates of chlamydia, gonorrhoea, condyloma acuminata and genital herpes, as well as total notifications for HIV/AIDS and syphilis during the pandemic versus previous years in Japan. We used a quasi-Poisson regression to determine whether any given week or month between January 2018 and December 2021 had a significant excess or deficit of STIs. Notification values above or below the 95% upper and lower prediction thresholds were considered as statistically significant. The start of the pandemic was defined as January 2020., Results: Chlamydia generally remained within predicted range during the pandemic period. Reporting of gonorrhoea was significantly higher than expected throughout early-to-mid 2021 but otherwise generally remained within predicted range prior to 2021. Condyloma, herpes and HIV/AIDS reporting were transiently significantly lower than expected throughout the pandemic period, but no significant periods of higher-than-expected reporting were detected. Syphilis showed widespread evidence of significantly lower-than-predicted reporting throughout 2020 but eventually reversed, showing significantly higher-than-predicted reporting in mid-to-late 2021., Conclusions: The COVID-19 pandemic was associated with variable changes in the reporting of STIs in Japan. Higher-than-predicted reporting was more likely to be observed in the later phases of the pandemic. These changes may have been attributable to pandemic-related changes in sexual behaviour and decreased STI clinic attendance and testing, but further research on the long-term impact of the pandemic on STIs is necessary., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
19. Progressive Cytopenia Developing during Treatment of Cryptococcosis in a Patient with HIV Infection and Bone Marrow Cryptococcal Infection.
- Author
-
Katsura M, Okuhama A, Koizumi Y, Ando N, Yanagawa Y, Mizushima D, Aoki T, Tsukada K, Teruya K, Kikuchi Y, Oka S, and Watanabe K
- Subjects
- Antifungal Agents therapeutic use, Bone Marrow, Flucytosine therapeutic use, Humans, Cryptococcosis complications, Cryptococcosis diagnosis, Cryptococcosis drug therapy, Cryptococcus neoformans, HIV Infections complications, HIV Infections drug therapy, Meningitis, Cryptococcal complications, Meningitis, Cryptococcal diagnosis, Meningitis, Cryptococcal drug therapy
- Abstract
Cytopenia is a common complication in patients with human immunodeficiency virus (HIV) infection. Identifying the cause is demanding because of the wide range of possible diagnoses. We herein report an HIV-infected patient with disseminated cryptococcosis involving multiple organs including the blood, brain, lungs, and bone marrow, who developed progressive pancytopenia after initiation of anti-fungal treatment with liposomal amphotericin-B (L-AMB) and flucytosine (5FC). The pancytopenia persisted despite early 5FC discontinuation. A bone marrow biopsy revealed cryptococcal infiltration and the blood examination findings recovered quickly after resuming L-AMB. Thus, this HIV-infected patient's pathological findings and clinical course suggested that the primary cause of the pancytopenia was bone marrow cryptococcosis.
- Published
- 2022
- Full Text
- View/download PDF
20. Imported African Tick Bite Fever in Japan: A Literature Review and Report of Three Cases.
- Author
-
Ando N, Kutsuna S, Takaya S, Katanami Y, and Ohmagari N
- Subjects
- Humans, Japan epidemiology, Travel, Rickettsia Infections diagnosis, Rickettsia Infections epidemiology, Rickettsia Infections microbiology, Spotted Fever Group Rickettsiosis diagnosis, Spotted Fever Group Rickettsiosis epidemiology, Tick-Borne Diseases diagnosis, Tick-Borne Diseases epidemiology, Tick-Borne Diseases microbiology
- Abstract
African tick bite fever (ATBF) is an acute febrile illness caused by Rickettsia africae. ATBF is an important differential diagnosis of acute febrile illness among returned travelers. However, little information is available on ATBF cases imported to Japan, as only seven have been reported to date. To characterize the epidemiological and clinical profiles of patients diagnosed with ATBF in Japan, we reported three new ATBF cases at our hospital between May 2015 and April 2018 and conducted a literature review.
- Published
- 2022
- Full Text
- View/download PDF
21. Modified self-obtained pooled sampling to screen for Chlamydia trachomatis and Neisseria gonorrhoeae infections in men who have sex with men.
- Author
-
Ando N, Mizushima D, Watanabe K, Takano M, Shiojiri D, Uemura H, Aoki T, Yanagawa Y, Kikuchi Y, Oka S, and Gatanaga H
- Subjects
- Adult, Ambulatory Care Facilities, Homosexuality, Male, Humans, Japan epidemiology, Male, Middle Aged, Nucleic Acid Amplification Techniques methods, Pharynx microbiology, Prospective Studies, Rectum microbiology, Sensitivity and Specificity, Urine microbiology, Chlamydia Infections diagnosis, Chlamydia trachomatis isolation & purification, Gonorrhea diagnosis, Mass Screening methods, Neisseria gonorrhoeae isolation & purification, Sexual and Gender Minorities, Specimen Handling methods
- Abstract
Objectives: To assess whether pooled sample testing with nucleic acid amplification tests was a potential alternative to three single-site sample testing to screen for Chlamydia trachomatis and Neisseria gonorrhoeae infections in asymptomatic men who have sex with men., Methods: We prospectively compared pooled sample testing with single-site sample testing in asymptomatic MSM. Self-obtained paired rectal samples, one gargle sample and one first-void urine sample were collected from participants to generate two sets of samples: one for pooled sample testing and the other for single-site testing. We used modified pooled sampling, which is defined as the use of gargle samples, instead of swabs, for the pooled sample to test for pharyngeal infection., Results: This study included 513 MSM. The positive rates of C. trachomatis and N. gonorrhoeae were 20.3% and 11.7%, respectively, for single-site sample testing. Compared with the sensitivity of single-site testing as the gold standard, the sensitivities of pooled sample testing for C. trachomatis and N. gonorrhoeae were 94.2% (95% CI 88.0% to 97.3%) and 98.3% (95% CI 90.9% to 99.9%), respectively. The concordance rate and kappa coefficient were 98.3% (95% CI 96.7% to 99.2%) and 0.945 (95% CI 0.859 to 1.000), respectively, for C. trachomatis and 98.8% (95% CI 90.1% to 100%) and 0.943 (95% CI 0.857 to 1.000), respectively, for N. gonorrhoeae ., Conclusions: The modified pooled sampling had a comparably high consistency with single-site sample testing. The results strongly suggest that the gargle sample is suitable as a part of pooled sample for STI screening of C. trachomatis and N. gonorrhoeae ., Competing Interests: Competing interests: SO has received research grants/materials from Gilead Sciences, MSD KK, CSL Behring and ViiV Healthcare, Co., and has received honorarium for lectures from MSD KK, Gilead Sciences, ViiV Healthcare and Janssen Pharmaceutical, KK., (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
22. High prevalence of circulating dual-class resistant Mycoplasma genitalium in asymptomatic MSM in Tokyo, Japan.
- Author
-
Ando N, Mizushima D, Takano M, Mitobe M, Miyake H, Yokoyama K, Sadamasu K, Aoki T, Watanabe K, Uemura H, Yanagawa Y, Gatanaga H, and Oka S
- Abstract
Objectives: To assess the prevalence and antibiotic resistance profile of Mycoplasma genitalium detected from urogenital/rectal swab samples obtained from MSM in Tokyo, Japan., Methods: We performed PCR-based screening for M. genitalium urogenital/rectal infection in 982 asymptomatic MSM between 1 January 2019 and 5 November 2020. Mutations in the antibiotic resistance-associated genes gyrA and parC and the 23S rRNA of M. genitalium were analysed., Results: The prevalence of M. genitalium infection was 6.1%: the prevalence of rectal and urogenital infection was 4.7% and 1.4%, respectively. Among the cases, 48 were successfully analysed for 23S rRNA, 41 for parC mutations and 37 for gyrA mutations. Macrolide- and quinolone-resistance associated mutations (23S rRNA and parC mutations) were observed in 43 (89.6%) and 28 (68.3%) cases, respectively. The quinolone-resistance associated mutation-harbouring variants also harboured macrolide-resistance associated mutations. The S83I mutation in the parC gene was most commonly identified (24 cases, 58.5%), and its combination with M95I or D99N mutation in the gyrA gene was observed in 9 of 36 successfully analysed cases (25.0%). No significant association was observed between the presence of antibiotic resistance and antibiotic exposure for either macrolides or fluoroquinolones ( P = 0.785 and 0.402, respectively)., Conclusions: In Tokyo, there is an alarmingly high prevalence of M. genitalium harbouring macrolide and/or quinolone resistance-associated mutations in MSM, irrespective of antibiotic exposure. The high prevalence of M. genitalium strains with both parC and gyrA mutations limits the efficacy of sitafloxacin. Therefore, suitable alternatives are required to treat such M. genitalium infections., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.